Trial Profile
A Phase III Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 With or Without HU Therapy in Patients With Sickle Cell Disease Who Have Had =>2 Acute Sickle-Related Painful Crises Within the Preceding 12 Months
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jul 2020
Price :
$35
*
At a glance
- Drugs Senicapoc (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms ASSERT
- Sponsors Icagen, Inc.; Neusentis
- 26 Jul 2020 Status changed from discontinued to completed. According to the ClinicalTrials.gov record, this trial was discontinued due to low probability of achieving the primary endpoint.
- 19 Aug 2008 New trial record.